Cytiva Files IPO Prospectus as a Leading Partner in Biopharmaceutical and Advanced Therapies Ahead of CSGCT 2025
01
Exhibitor Promotion
Cytiva
Booth No.: B10
Cytiva is a pioneer in the life sciences sector, dedicated to advancing unseen technologies and accelerating extraordinary therapies.With a rich heritage spanning centuries, we leverage our extensive technical expertise, talent pool, diverse and broad product portfolio, and exceptional services to provide critical support to researchers and biopharmaceutical companies across all stages—from drug discovery to commercialization—thereby advancing the accessibility of innovative therapies.
Cytiva actively collaborates with researchers in academia and translational medicine, as well as biotechnology developers and manufacturers, focusing on research into biopharmaceuticals, cell and gene therapies, and a range of innovative technologies represented by mRNA. By enhancing the speed, efficiency, flexibility, and capabilities of drug development and bioprocessing, Cytiva enables the development and production of transformative medicines and therapies to benefit patients worldwide.
Cytiva isDanaherAn independently operated company under the Danaher Group, working hand in hand with Danaher’s Diagnostics and Life Sciences businesses to harness innovation and partner with customers in advancing a healthier future for humanity.
02
Exhibit Introduction
ELEVECTA Stable Producer Cell Line
ELEVECTA Stable Producer Cell Lines are specifically designed and developed for stable and simplified AAV production. Drawing on years of experience and expertise in monoclonal antibody production using CHO cells, the ELEVECTA Stable Producer Cell Lines stably integrate and genetically express the essential genes required for AAV production—including Rep, Helper, Capsid, and the Gene of Interest (GOI)—within the host cells. This enables a production process that eliminates the need for plasmids, transfection, or helper viruses, thereby simplifying upstream processes, enhancing AAV production stability, and reducing batch-to-batch variability. By breaking down current industry barriers in AAV manufacturing, this platform facilitates robust scale-up to large-scale production and lowers drug manufacturing costs, representing the future trend in viral vector production.
EuLV: Lentiviral Vector Production System Based on Stable Cell Lines
This system utilizes inducible stable cell lines to produce lentiviral vectors in chemically defined media through high-cell-density suspension culture. By eliminating the need for plasmids and transfection reagents, this approach simplifies the lentiviral vector production process and reduces associated quality control and operational costs. Production via stable cell lines overcomes the limitations of transient transfection, enhancing the uniformity and titer of lentiviral vectors while facilitating better control over batch-to-batch variability. Furthermore, high-density suspension culture of these stable cell lines increases viral yield per unit volume, reduces the number of production batches required, and meets the demands for large-scale manufacturing of lentiviral vectors.
Sefia Select Cell Processing System
The Sefia Select Cell Processing System, comprising hardware (the Sefia S-2000 Cell Processor and Sefia Select accessories), dedicated software applications, and single-use consumable kits, provides a comprehensive solution for your cell processing needs. This automated, closed-system platform performs critical cell processing steps—including cell separation, cell harvesting, and formulation aliquoting—enabling you to establish a robust, standardized manufacturing workflow for cell therapy products.
2025 CSGCT Conference
To drive technological breakthroughs, industrial integration, policy alignment, and international cooperation in China’s cell and gene therapy (CGT) sector, and to propel the Chinese CGT industry to the forefront of global competition, the China Society for Gene and Cell Therapy (CSGCT) Conference was established.
Building on its close ties with the American Society of Gene & Cell Therapy (ASGCT), the 2025 CSGCT Annual Meeting will bring togetherGlobal Excellence in Sciencefamilies, clinical experts, multinational pharmaceutical companies, and overseas investment institutions, bringing the most cutting-edge developments in the global field of cell and gene therapy.Cutting-edge research advancements, technologies and applications, market access information, high-quality collaboration opportunities, and overseas investors and investment needsSeeking Collaboration: Building a Platform for In-Depth Exchange and Cooperation Between China’s Cell and Gene Therapy Industry and the Global Industrial Chain.
The conference closely addressed the industry’s hotspots, pain points, and bottlenecks, featuring1 Main Forum + 15 High-End Sub-Forums, coveringLatest Advances in Global Gene Therapy, Immune Cell Therapy, In Vivo CAR-T, Adult Stem Cells and Exosomes, iPSC-Derived Cell Therapies, Small Nucleic Acid Drugs, Gene Editing, Oncolytic Viruses, and Tumor Vaccines, as well as CMC and Testing, AI-Driven Drug R&D, Registration and Regulation, Investment and Financing, and BD MatchmakingWaitComprehensive coverage across the entire industry chain.
2025 The 2nd China Society for Gene and Cell Therapy (CSGCT) Congress
September 12-13, 2025
Zhongguancun National Independent Innovation Demonstration Zone Exhibition and Trading Center [Conference Center]
For more details, please scan the QR code to visit the official conference website.
The 2025 2nd China Society for Gene and Cell Therapy (CSGCT) Congress specially planned“2025 CSGCT Conference Project Pitch Session”, bringing together over 1,000 high-quality investment institutions from China and abroad, industrial investors, and decision-makers of government industrial guidance funds; attracting multinational corporations (MNCs) as well as renowned domestic and international medical and pharmaceutical companies seeking business development (BD) collaborations with outstanding projects, products, and technologies; and accelerating the exchange and cooperation on the most distinctive new technologies, new products, and new ecosystems in China’s cell and gene therapy (CGT) sector.
Conference Forum Details
Speech/Sponsorship/Exhibition & Business Cooperation Inquiries
Ms. Li: 18600921680 (WeChat available)
Registration / Business Delegation Inquiry
Ms. Ren: 15111945514 (WeChat ID same as phone number)